Fed Circ upholds three Teva patents, axes others

The US Court of Appeals for the Federal Circuit has affirmed US Patent Trial and Appeal Board’s (PTAB) decisions upholding three patents related to Teva Pharmaceutical’s migraine drug Ajovy, but has invalidated six others.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Actavis and Teva sued over narcotic addiction generic

1 March 2017 Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex.

Americas

Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic

25 February 2021 A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.

More on this story

Americas

Actavis and Teva sued over narcotic addiction generic

1 March 2017 Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex.

Americas

Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic

More on this story

Americas

Actavis and Teva sued over narcotic addiction generic

1 March 2017 Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex.

Americas

Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic